Hyperhidrosis Clinical Trial
Official title:
Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis
| NCT number | NCT02100072 |
| Other study ID # | CYN13-MK-HH01 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | June 2013 |
| Est. completion date | April 2015 |
| Verified date | December 2020 |
| Source | Cynosure, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
| Status | Completed |
| Enrollment | 5 |
| Est. completion date | April 2015 |
| Est. primary completion date | April 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 55 Years |
| Eligibility | Inclusion Criteria: - A healthy non-smoking male or female between 18-55 years of age - Understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment - Understand and accept the obligation and is logistically able to present for all scheduled follow-up visits - Clinically diagnosed for primary hyperhidrosis of the axilla. - A self-assessed Hyperhidrosis Disease Severity Scale (HDSS) score of three (3) or four (4) Exclusion Criteria: - Clinical diagnosis of secondary hyperhidrosis - Uncontrolled systemic disease or infection - Concurrent use of any hyperhidrosis treatments other than over the counter antiperspirants or deodorants - Receipt of Botox® or Dysport® within the past six months - Patients who refuse to stop using over the counter antiperspirants 24 hours prior to the day of surgery and each of the follow-up visits at 3 months and 6 months that Minors starch iodine tests may be performed. - Patients using or having used within 7 days of baseline visit: cholinomimetic agents, anticholinergic agents, prescription antiperspirants, any herbal medicine treatments or any other treatments for hyperhidrosis except over the counter antiperspirant or planning to use such agents during the course of the study. - Any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; OR any other types of treatments for hyperhidrosis in the area to be treated in the past 6 months - Has any other medical condition, that, in the investigator's opinion would interfere with the subject's participation in the study - Is susceptible to light induced seizures or history of seizures - Has a history of keloid formation - Significant cardiovascular disease - Bleeding disorders - Anti-platelet and anticoagulant medication - Sensitivity to lidocaine or epinephrine - Pregnancy or planned pregnancy - Existing neuromuscular disorders (myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis) - Electronic implants - Subjects requiring supplemental oxygen - Has therapies or medications which may interfere with the treatment (including medications causing photosensitivity - Allergic to Doxycycline |
| Country | Name | City | State |
|---|---|---|---|
| United States | Skin Care Physicians | Chestnut Hill | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Cynosure, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in Sweating Assessed Using Gravimetry | A gravimetry test was performed to determine the quantity of sweat produced, comparing the post-treatment to the baseline numbers. A pre-weighted filter paper was placed on the armpit, and then weighed afterwards to determine the quantity of sweat produced. To calculate the change between the baseline and 3 months post baselines, the values taken at these 2 time points are subtracted from each other. A negative value means that there has been a decrease in gravimetric weight since the baseline. | Baseline and 3 months post baseline |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04924036 -
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
|
Phase 2 | |
| Recruiting |
NCT05102396 -
Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?
|
Phase 2 | |
| Recruiting |
NCT04178161 -
Image Guided Targeted Photoablation for the Treatment of Localized Hyperhidrosis
|
N/A | |
| Completed |
NCT02552199 -
A Non-Interventional Study To Assess Sweating
|
||
| Completed |
NCT02565732 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
|
Phase 2 | |
| Recruiting |
NCT01930604 -
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
|
Phase 2 | |
| Completed |
NCT01811004 -
Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
|
N/A | |
| Completed |
NCT01671800 -
Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating
|
Phase 1 | |
| Completed |
NCT01956591 -
Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis
|
N/A | |
| Completed |
NCT01934153 -
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
|
Phase 1 | |
| Completed |
NCT06113978 -
Thoracoscopic Sympathetic Chain Interruption for Palmar Hyperhidrosis in Patients Below 18
|
N/A | |
| Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
| Completed |
NCT04906655 -
An Open Label Study for Palmar Hyperhydrosis
|
Phase 2 | |
| Completed |
NCT02563899 -
Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
|
Phase 2 | |
| Withdrawn |
NCT05546710 -
miraDry Post Market Tumescent Anesthesia Study
|
N/A | |
| Completed |
NCT02016885 -
A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
|
Phase 2 | |
| Completed |
NCT00168480 -
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
|
Phase 4 | |
| Completed |
NCT03416348 -
Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2
|
Phase 1 | |
| Completed |
NCT02973659 -
The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.
|
N/A | |
| Recruiting |
NCT05805696 -
Treatment and Mapping of Impostor Phenomenon
|
N/A |